Whilst the initial capital outlay could be considered a small outlay, substantial royalties will need to be paid to the vendors year in year out if it is successful. IIRC it could be in the low 100s of millions each year if wildly successful which imo goes a long way to explaining why it appears that BOT acquired what is described as potentially being a cash cow for what, at first glance, appears to be a cheap price.
Ann: BOT Submits FDA New Drug Application for Sofpironium Bromide, page-35
-
- There are more pages in this discussion • 138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 38.0¢ | 35.0¢ | $4.519M | 12.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 75362 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 326113 | 17 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |